Solara Active Pharma Sciences share price today

Solara Active Pharma Sciences Ltd's share price was ₹644.90 at the close on 4 November 2026. It has been rising for 19 weeks. That is 9.2% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 12 weeks in a row.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Solara Active Pharma Sciences Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹441 and ₹749, and at that close it sat 66% of the way up from that low.

Over the last 8.3 years the share price moved +208% while the NIFTY 500 moved +138%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: highest quarterly profit in 16 quarters, operating margin up 7 points on a year earlier and revenue up on a year earlier for 4 quarters in a row.

1. Highest quarterly profit in 16 quarters

   Profit of ₹28 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Profit rose because the base business sold more.

   Next results: check whether profit stays at or above this quarter's level for another two quarters, the CEO's own test for a turnaround.

   From the earnings call on 16 Oct 2026.

2. Operating margin up 7 points on a year earlier

   18% in the September 2026 quarter, from 11%.

   Why: Operating margin rose because operating costs stayed broadly flat, so more of the extra gross profit reached operating profit.

   Next results: check whether customer price increases cover the higher raw material costs from West Asia, so the base gross margin starts to recover.

   From the earnings call on 16 Oct 2026.

3. Revenue up on a year earlier for 4 quarters in a row

   In the September 2026 quarter revenue was ₹417 crore, +32.8% on a year earlier.

   Why: Revenue rose because demand for the base business's active ingredients was good, with more customers and products made.

   Next results: check whether the three remaining drug filings are submitted by the end of the fiscal year.

   From the earnings call on 16 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Solara Active Pharma Sciences reported revenue of ₹417 crore, up 32.8% from ₹314 crore a year earlier, and a profit of ₹28.0 crore, against a loss of ₹10.0 crore a year earlier.

Solara Active Pharma Sciences results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Solara Active Pharma Sciences' management discussed these results on a call held on 16 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Solara Active Pharma Sciences closed at ₹644.90 on 4 November 2026, up 14.1% from ₹565.05 a year earlier (7 November 2025) and down 44.1% over five years. Its highest weekly close since June 2018 was ₹1,637.51 on 6 August 2021.

Solara Active Pharma Sciences share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

443 weekly closes from 29 June 2018 to 4 November 2026.

4 Nov 2026: Solara Active Pharma Sciences closed at ₹644.90, up 1.9% on the week and down 9.8% on the month. 16 Oct 2026: Solara Active Pharma Sciences held its results call for July to September 2026. Management guided: FY27 goal of five DMF submissions, with two completed and three more hoped for by year-end.

Earlier

• Results for July to September 2026: Revenue up 32.8% on a year earlier.

Solara Active Pharma Sciences paid no dividend in the 12 months to 5 November 2026. The last was a dividend of ₹3 a share, ex-date 18 August 2021.

Solara Active Pharma Sciences dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Not in its latest year. Solara Active Pharma Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 9 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 16 October 2026, Solara Active Pharma Sciences' management guided: FY27 goal of five DMF submissions, with two completed and three more hoped for by year-end.

“I would say we have turned around if we can deliver another 2 quarters in line with the current quarter or better than the current quarter. That would qualify as a turnaround for me.”Sandeep, on the call for July to September 2026

What management guided

• Strategic review outcome and next steps within 12 weeks.
• Base-business gross margin of 52-55% viewed as sustainable over the medium to long term.
• West Asia-driven base gross-margin pressure likely to persist for at least 1-2 more quarters.
• Net debt/operating profit expected to remain in a similar range over the medium term.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 16 October 2026.

When Solara Active Pharma Sciences reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ibuprofen, Vizag and CRAMS strategy outcome - check for a named operating path, customer process or multiproduct use.

Solara Active Pharma Sciences is on 2 of our India lists: Momentum stocks and Pharma stocks.

Solara Active Pharma Sciences Ltd earned ₹28.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹7.0 Cr. That is 6.7% of the quarter's revenue. The same quarter a year earlier lost ₹10.0 Cr. 6 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was −₹7.0 Cr (−800.0% on the year before).

Solara Active Pharma Sciences Ltd reported ₹417 Cr of revenue in the Sep 2026 quarter, +32.8% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 8 years it has grown 12.8% a year on average. The last full year, FY26, came in at ₹1,369 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,535 Cr.

FY26 revenue was ₹1,369 Cr, +6.6% on the year before.

Recent pace: the last four quarters grew +27.6% on average, against 12.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +27.3%, against +12.1% a year over the last 8 quarters (accelerating).

Solara Active Pharma Sciences Ltd's operating margin was 18.0% in the Sep 2026 quarter, 7.0 percentage points higher than the same quarter a year ago. Across 9 years it has been between −7.0% and 24.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +7.3 percentage points on the year while gross margin changed −2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 181% of Solara Active Pharma Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹153 Cr of operating cash against −₹7.0 Cr of profit. After ₹70.0 Cr of spending on assets, ₹83.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 181% of profit came in as cash: the cash cycle got 38 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Solara Active Pharma Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 140 days in FY26, up from 102 days in FY21. It spent ₹143 Cr on assets over the last 3 years. Customers take 117 days to pay, and stock sits for 170 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,369 Cr, each day of that cycle ties up about ₹3.8 Cr, so roughly ₹525 Cr is tied up in the business at any time.

FY26: customers took 117 days to pay and stock sat for 170 days, about 5.6 months of sales sitting as stock, for a full cycle of 140 days, longer than FY21's 102.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 170 days. Customers pay about 117 days after that. Suppliers are paid at 146 days. Together that makes the 140-day cycle.

Spending on assets: ₹143 Cr over the last 3 years, against ₹302 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹205 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Solara Active Pharma Sciences Ltd's P/E is 66.1×, in the middle of its own history: higher than 66% of past readings. Its usual P/E (the middle reading) is 33.2×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹7.07.

Why the multiple is where it is: over the past year earnings per share moved −1,466.7% while the price moved +14.1%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved −11.0% a year; about −27.3% a year came from earnings growth and about +16.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Solara Active Pharma Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Solara Active Pharma Sciences Ltd earned a ROCE of 5% in FY26. That is up from a low of −9% in FY24. Its return on capital used (ROIC) is 5.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a −0.5% net margin and 0.59× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −0.5% net margin × 0.59× asset turnover × 1.86× leverage (assets divided by equity) ≈ −0.5% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 6.8% − 12.0% = −5.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 6.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 4.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Solara Active Pharma Sciences Ltd has total debt of ₹591 Cr against shareholder equity of ₹1,439 Cr as of Sep 2026, so its debt is 0.41× its equity. Year by year, that ratio went from 0.68 in FY22 to 0.55 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.